BACKGROUND: Ahyaluronate formulation for viscosupplementation, Hymovis (HYADD4) has been proposed for treating osteoarthritis (OA) through a single injection instead of two. This study aimed to compare the safety and performance of two different doses of a single Hymovis injection to those of Synvisc-One, a well-known single-injection formulation. METHODS: Sixty OApatients were prospectively recruited and randomly assigned to a single injection of Hymovis 4 mL/32mg (N.=20, age 63±9 years) or 6 mL/48 mg (N.=22, age 67±8 years), or Synvisc-One 6 mL/48 mg (N.=20, age 64±10 years), and assessed through the Western Ontario McMaster University Osteoarthritis index (WOMAC) on a monthly basis up to 6 months. RESULTS: Two patients treated with Synvisc-One withdrew due to injection site joint inflammation. A significant improvement in OA symptoms was observed for all study groups at all time points following injection. No significant differences were observed among the treatment groups for all the study performance and safety endpoints. CONCLUSIONS: One injection of Hymovis 4 mL/32 mg was as safe and effective as one injection of Synvisc-One 6 mL/48 mg and should be the preferred dosage in the treatment of symptomatic knee OAby single intra-articular injection.
Dose-response of hyaluronate-based viscoelastic hydrogels for the treatment of knee osteoarthrosis: A prospective, randomized, comparative clinical trial
Bernetti A.;
2020-01-01
Abstract
BACKGROUND: Ahyaluronate formulation for viscosupplementation, Hymovis (HYADD4) has been proposed for treating osteoarthritis (OA) through a single injection instead of two. This study aimed to compare the safety and performance of two different doses of a single Hymovis injection to those of Synvisc-One, a well-known single-injection formulation. METHODS: Sixty OApatients were prospectively recruited and randomly assigned to a single injection of Hymovis 4 mL/32mg (N.=20, age 63±9 years) or 6 mL/48 mg (N.=22, age 67±8 years), or Synvisc-One 6 mL/48 mg (N.=20, age 64±10 years), and assessed through the Western Ontario McMaster University Osteoarthritis index (WOMAC) on a monthly basis up to 6 months. RESULTS: Two patients treated with Synvisc-One withdrew due to injection site joint inflammation. A significant improvement in OA symptoms was observed for all study groups at all time points following injection. No significant differences were observed among the treatment groups for all the study performance and safety endpoints. CONCLUSIONS: One injection of Hymovis 4 mL/32 mg was as safe and effective as one injection of Synvisc-One 6 mL/48 mg and should be the preferred dosage in the treatment of symptomatic knee OAby single intra-articular injection.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
